MicroRNAs (miRNAs), some small non-coding RNAs that regulate gene expression at the posttranscriptional level, are always aberrantly expressed in carcinomas. In this study, we found that miR-23b-3p was remarkably up-regulated in human esophageal squamous cell carcinoma cells and tissues. Moreover, miR-23b-3p could induce the proliferation, invasion, and metastasis in vitro. EBF3 was identified as the direct downstream target gene of miR-23b-3p and ectogenic EBF3 could strongly inhibit the proliferation, invasion, and metastasis in vitro. Furthermore, it was found that miR-23b-3p could regulate epithelial-to-mesenchymal transition progress by blocking EBF3. Therefore, it was concluded that miR-23b-3p targeted EBF3 to accelerate the proliferation, invasion, and metastasis in ESCC.
Introduction
Esophageal squamous cell carcinoma (ESCC) is one of the major histological subtypes of esophageal cancer in China and more than 80% of the patients are male [1] [2] [3] . This carcinoma constitutes a serious threat to human health globally because of its high incidence of new cases annually. Although substantial progresses have been realized in chemo-and radio-therapies, advanced ESCC still remains an extremely poor prognosis for patients [4, 5] .
MicroRNAs (miRNAs), having~22 nucleotides, are short noncoding RNA molecules that regulate gene expression at the posttranscriptional level [6, 7] . Recent researches have reported that miRNAs can be involved in the development and progression of ESCC [8] . MiR-23a and miR-23b are found to be highly expressed in the plasma of ESCC patients, supported by the microarray data from the Department of Oncology, Shanghai Jimin Hospital (Shanghai, China) [9] . However, the underlying biological mechanisms about the tumorigenesis in ESCC and the significant role of miR-23b-3p in carcinogenesis remain unclear.
In our present study, miR-23b-3p was found to be frequently up-regulated in ESCC cells. Then, miR-23b-3p was clarified to be able to induce the proliferation, invasion, and metastasis. EBF3 was further identified as the direct downstream target gene of miR-23b-3p and ectogenic EBF3 could obviously inhibit the proliferation, invasion, and metastasis in ESCC cell lines. Furthermore, it was also found that miR-23b-3p could promote epithelial-to-mesenchymal transition (EMT) progress, which might be blocked by EBF3. Therefore, it was concluded that miR-23b-3p targeted EBF3 to accelerate the proliferation, invasion, and metastasis in ESCC.
Cell Bank of the Chinese Academy of Medical Science (Beijing, China) and cultured in Roswell Park Memorial Institute (RPMI)-1640 medium (Sigma, St Louis, USA) with 10% of Fetal Bovine Serum (FBS; Gibco, Carlsbad, USA) and 1% of penicillin/streptomycin (Beyotime, Nanjing, China) at 37°C in a humidified chamber with 95% air and 5% CO 2 .
RNA extraction and qRT-PCR analysis
Total RNAs were extracted from the cultured cells by using TRIzol reagent (Takara, Dalian, China) according to the manufacturer's instructions, and the concentration was measured by a spectrophotometer. Reverse transcription was performed in a 20 μl reaction system, including total RNA at 1 μg/μl final concentration, oligo dT primer and Thermoscript reverse transcriptase (Invitrogen) at 60°C. The expression of miR-23b-3p, EBF3, E-cadherin, β-catenin, N-cadherin, and Vimentin were measured by qRT-PCR with SYBR Green (abm, Nanjing, China) and a STEP ONE RT-PCR apparatus (Applied Biosystems, Foster, USA). PCR conditions were set at 95°C for 5 min, 40 cycles of 60°C for 30 min. The primers used are listed in Table 1 . Relative gene expression levels were calculated by the ΔΔCt method. All reactions were performed in triplicate.
Prediction of the downstream target gene of miRNA
Five established miRNA-target prediction programs (TargetScan, miRanda, PicTar, MirTarget2, and PITA) were used to predict the target genes of miRNA. The downstream target genes of miR-23b-3p were predicted by the selected five independent tools. Each tool was employed at least three independent times.
Cell transfection and plasmids construction
Because the expression of miR-23b-3p in TE1 and TE10 cell lines were higher than other cell lines, we chose these two cell lines for further experiments for further cellular functional experiments. MiR23b-3p mimics (miR-23b-3p, CUCAGGUGCUCUGGCUGC), mimics NC (miR-NC, UUCUCCGAACGUGUCACGU), and miR-23b-3p inhibitor (anti-miR-23b-3p, UCUCAGUGCUUCUGGCUGC), inhibitor NC (anti-miR-NC, UCUACUCUUUCUAGGAGGUUGUGA) were synthesized by Genechem Company (Shanghai, China). EBF3 overexpression plasmid was purchased from the Genechem Company and named as EBF3. All of the plasmids were confirmed by DNA sequencing. Cells were transfected by Lipofectamine 2000 (Invitrogen, Carlsbad, USA) or RNA mate (GenePharma, Shanghai, China) in opti-RPMI 1640 (Gibco) without FBS according to the manufacturer's protocols.
Western blot analysis
The total cellular proteins were extracted by using ice-cold RIPA reagent (Beyotime) containing 45 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% Triton X-100, phenylmethanesulfonyl fluoride (PMSF), and cocktail of protease inhibitor. Equal amounts of protein lysates were subject to 10% SDS-PAGE and were electrophoretically transferred to polyvinylidene difluoride membranes (PVDF) (Millipore, Bedford, USA). The membrane was blocked with 5% of skim milk and then incubated with the rabbit anti-human EBF3 antibody (1:1000) and anti-GAPDH antibody (1:5000) overnight at 4°C, followed by incubation with horseradish peroxidase-conjugated secondary antibodies for 2 h at 37°C. All antibodies were purchased from Abcam (Cambridge, UK). The proteins were visualized by the enhanced chemiluminescence kit (Pierce, Rockford, USA) and the bands were exposed to X-ray film (Kodak, New York, USA). GAPDH was used as the internal reference. All reactions were performed in triplicate.
Immunofluorescence staining
Cells were transplanted on sterilized cover slips and cultured for 24 h, then fixed with ice-cold acetone for 20 min, washed with PBS, incubated with rabbit anti-E-cadherin, N-cadherin, Vimentin, and β-catenin antibodies overnight at 4°C, blocked with 1% of BSA for 30 min at 37°C, and stained with FITC-conjugated goat anti-rabbit IgG secondary antibodies (Cell Signaling Technology, Beverly, USA) for another 30 min at 37°C. Then, the cell nuclei were counterstained with DAPI (Cell Signaling Technology) for 5 min at 37°C. The cover slips were mounted and imaged under a fluorescence microscope (Olympus, Tokyo, Japan). All reactions were performed in triplicate.
Luciferase reporter gene assay
The luciferase reporter gene assay was conducted on 96-well plates according to the manufacturer's instructions (Dual-Glo Luciferase Assay System; Promega, Madison, USA). The pLUC firefly luciferase vectors contained empty, wild-type, and mutant EBF3 3′-UTR sequence, respectively. EBF3 plasmid was constructed and the fragment containing putative binding sites was amplified. Lipofectamine 2000 (Life Technologies, Carlsbad, USA) was used for co-transfection. Luciferase activity was detected at 48 h after transfection. The relative luciferase activities were normalized by Renilla luciferase activities. Each sample was measured in triplicate.
Methylthiazolyldiphenyl-tetrazolium bromide proliferation assay
Cell proliferation was analyzed by methylthiazolyldiphenyl-tetrazolium bromide (MTT) assay. Cells were seeded into 96-well plates at 6000 Table 1 . Sequence of primers used in qRT-PCR
Gene
Forward primer Reverse primer
cells per well in a final volume of 100 ml and cultured for 1-3 days. Then, 20 μl of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) solution (1 mg/ml; Sigma, St Louis, USA) was added into each well and incubated for 4 h at 37°C. After the medium was removed at 24, 48, and 72 h, respectively, the remaining MTT formazan crystals were solubilized in 100 μl of DMSO (Sigma). The OD value of each well representing the relative number of surviving cells was measured with a microplate reader (BioTek, Beijing, China) at 560 nm. Each experiment was carried out in triplicate.
In vitro transwell assays
Cell migration and invasion were detected by using Transwell chamber with 8.0-μm pore size and 6.5 mm diameter (Corning Co., Corning, USA 
Statistical analysis
Data were expressed as the mean ± SD from at least three independent experiments. Continuous data were compared between groups by using the Mann-Whitney U test. Categorical variables were compared by means of Fisher's exact test. In vitro MTT, transwell assays, qRT-PCR, and luciferase activities were analyzed by the Student's t-test. Multiple-group comparisons were analyzed by oneway ANOVA. All statistical analyses were performed with SPSS19.0 software (SPSS Inc., Chicago, USA). P < 0.05 was considered statistically significant.
Results

MiR-23b-3p was up-regulated in ESCC cells
To confirm the expressions of miR-23a and miR-23b in ESCC, qRT-PCR was employed to assess the expressions of miR-23a, miR23b-5p and miR-23b-3p in six ESCC cell lines. It was found that the levels of miR-23a, miR-23b-5p, and miR-23b-3p were all higher in ESCC cell lines than that in human normal esophageal squamous epithelial cell line (HEEC). Moreover, dysregulated expression of miR-23b-3p was the most remarkable in these cell lines (Fig. 1) .
MiR-23b-3p facilitated the proliferation, invasion, and metastasis of ESCC cells
To further verify the biological functions of miR-23b-3p in ESCC, we used miR-23b-3p over-expression ESCC cell lines TE1 and TE10 to perform the cellular functional experiments. Both the two ESCC cell lines were transfected with miR-23b-3p inhibitor. MTT assay revealed that miR-23b-3p down-regulation significantly inhibited cell proliferation compared with the negative control at 24, 48, and 72 h ( Fig. 2A) . For the migration and invasion assays, the down-regulation of miR-23b-3p significantly decreased the number of migrated and invaded cells compared with negative control (Fig. 2B,C) . These results suggested that miR-23b-3p may be an oncogene that could induce proliferation, invasion, and metastasis in vitro ESCC cells.
EBF3 was confirmed as a direct target of miR-23b-3p in ESCC cells
To further investigate the underlying mechanism, we analyzed the downstream targets of miR-23b-3p by means of online target prediction tools (TargetScan, miRanda, and miRTarget). It was found that EBF3 might be a potential target. Then, luciferase reporter gene assay was performed to confirm the downstream target. The relative luciferase activity of the wild-type EBF3 co-transfected with miR23b-3p mimics was prominently decreased than that of any others (Fig. 3A) . Furthermore, over-expressed miR-23b-3p could repress the EBF3 expression, and down-regulated miR-23b-3p could induce the EBF3 expression in ESCC cells (Fig. 3B,C) . These data indicated that EBF3 was the direct downstream target of miR-23b-3p and EBF3 was negatively modulated by miR-23b-3p in ESCC cells.
EBF3 inhibited the proliferation, invasion, and metastasis of ESCC cells
To identify the biological function of the downstream target EBF3 in ESCC, we transfected ectopic EBF3 into the ESCC cell lines. MTT assay demonstrated that over-expressed EBF3 could remarkably inhibit the cell proliferation compared with the negative control after 24, 48, and 72 h (Fig. 4A) . For migration and invasion assays, over-expression of EBF3 apparently decreased the number of migrated and invaded cells compared with the negative control (Fig. 4B,C) . These results suggested that EBF3 may be a cancer suppressor gene that could reduce proliferation, invasion, and metastasis of ESCC cells in vitro.
EBF3 reversed the abilities of proliferation, invasion, and metastasis induced by miR-23b-3p in ESCC cells
Since EBF3 was found to be the direct downstream target of miR23b-3p, we further explored whether EBF3 could reverse the ability of proliferation, invasion, and metastasis caused by miR-23b-3p in ESCC cells. qRT-PCR and western blot analysis showed that the expression of EBF3 was reversed by co-transfection with miR-23b-3p and EBF3 (Fig. 5A,B) . MTT assay showed that the proliferative Figure 1 . MiR-23b-3p was up-regulated in ESCC cells Expressions of miR23a, miR-23b-5p, and miR-23b-3p in HEEC and other six ESCC cell lines were detected by qPCR. The experiment was performed in triplicate. U6 was used as an internal control. **P < 0.01.
ability of miR-23b-3p mimics was strikingly lessened by cotransfection with miR-23b-3p and EBF3 at 24, 48, and 72 h (Fig. 5C ). Migration and invasion assays showed that the cellular migratory and invasive abilities were fascinatingly reserved by co-transfection with miR-23b-3p and EBF3 in ESCC cells (Fig. 5D,E) . These results indicated that EBF3 was regulated by miR-23b-3p and could reverse the abilities of proliferation, invasion, and metastasis of ESCC cells caused by miR-23b-3p in vitro.
EMT was regulated by the interaction of miR-23b-3p and EBF3 in ESCC cells
To figure out the metastasis mechanism of ESCC, we studied EMT progress initiated by miR-23b-3p and EBF3. qPCR and immunofluorescence staining assay were employed to assess the expression levels of EMT markers (E-cadherin, β-catenin, N-cadherin, and Vimentin) in ESCC cell lines. It was found that the epithelial markers (E-cadherin and β-catenin) in miR-23b-3p mimics-transfected cells were dramatically down-regulated compared with those in the miR-NC transfected cells. The mesenchymal markers (N-cadherin and Vimentin) in cells transfected with miR-23b-3p mimics were significantly up-regulated compared with those in cells transfected the negative control (Fig. 6A,B ). An expression analysis indicated that the epithelial markers (E-cadherin and β-catenin) in cells transfected with ectopic EBF3 were remarkably over-expressed compared with those in cells transfected with the negative control. The mesenchymal markers (N-cadherin and Vimentin) in cells transfected with ectopic EBF3 were obviously down-expressed compared with those in cells transfected with the negative control (Fig. 6C,D) . These results demonstrated that miR-23b-3p and EBF3 could affect ESCC cells to obtain mesenchymal phenotype and to lose the epithelial phenotype, followed by the strengthening of migration and metastasis.
Discussion
Esophageal cancer contains two main histologic types: squamous cell carcinoma (SCC) and esophageal adenocarcinoma (EAC) [10] . There are distinct epidemiologic differences between the two histologic types [11] . Although EAC is one of the most rapidly increasing cancers in Western countries, ESCC is still dominant in Southeast Asia, especially in China [12, 13] . ESCC now accounts for~90% of all esophageal cancer cases in China and it is one of the most lethal cancers in recent years [14] . The factors underlying the nosogenesis of ESCC are still unknown. Some studies have demonstrated that multiple genetic alterations, such as the activation of oncogene and the dysfunction of tumor-suppressor gene, are the possible mechanisms contributed to ESCC development [15] [16] [17] . MiRNAs are some short endogenous non-coding RNAs that are highly conserved and expressed in many species [18] . They are involved in biological and pathologic processes by acting as part of multi-protein complexes to silence the expression of target genes and transform the expression of many different genes [19, 20] . MiRNAs modify cell differentiation, proliferation, migration, apoptosis, and metabolism, and can function as oncogenes or tumor suppressors [21, 22] . Komatsu et al. reported that miR-23a and miR23b were noticeably more highly expressed in the pretreated plasma and tumor tissues of ESCC patients with a low histopathologic response than in those with a high histopathologic response. They concluded that in plasma miR-23a could be viewed as a helpful biomarker for clinical pathology feature to predict chemoresistance in ESCC patients [23] . MiR-23b-3p was recently found to be down-regulated in acute myeloid leukemia and involved in PrxIII which is a ROS scavenger [24] . Some scholars reported that miR-23b-3p could mediate ATG12 and HMGB2 to repress autophagy and sensitize gastric cancer cells to chemotherapy, implicating its potential use in drug resistance prediction and treatment [25] . Down-regulated miR-23b-3p was found in chondrosarcoma by miRNA array and qRT-PCR [26] . Correlation analysis showed that miR-23b was downexpressed in cutaneous T-cell lymphoma and an inverse relationship between miR-23b promoter methylation and miR-23b expression was revealed [27] . Moreover, miRNA profiling illustrated that miR23b in colorectal cancer patients was down-expressed with stage II and stage III disease [28] . By using genomic analysis and miRNA expression profiling analysis, Begum et al. [29] identified that the novel cancer-related miR-23b-3p could be a prognostic marker for the early stage non-small cell lung cancer and regarded miR-23b-3p as potential targeted therapy. Similar study about non-small cell lung cancer indicated that plasma exosomal miR-23b-3p was a promising non-invasive prognostic biomarker, because elevated levels of exosomal miR-23b-3p was independently associated with poor overall survival as revealed by the qPCR assay [30] . From signature distinguishing specimens in the melanoma cell lines, miR23b-3p was decreased in melanomas vs. nevi [31] . Other studies revealed that miR-23b-3p was down-expressed in follicular thyroid carcinomas, breast cancer, and glioma [32] [33] [34] .
Another study showed that miR-23b-3p could inhibit PTEN gene and was regarded as an oncogenic miRNA in renal cell carcinoma [35] . MiR-23b-3p also targeted SIRT1-dependent signaling pathway to regulate high-glucose-induced cellular metabolic memory in retinopathy [36] . In colorectal cancer, miR-23b took part in intrinsic drug resistance in colorectal cancer cell lines and could be predictive biomarkers for oxaliplatin [37] . In glioblastoma, miR23b-3p was down-regulated by hypoxia and was viewed as an oncogenic player [38] . At the same time, the microarray data of miRNA profiles from the Department of Oncology in Jimin Hospital also revealed that the expression of miR-23b-3p was up-regulated more remarkably in ESCC tissues than that in the human normal esophageal squamous epithelial tissues.
The early B-cell factors (EBFs) are DNA binding transcription factors that were first discovered in 1993 [39] . EBFs had the basic helix-loop-helix (bHLH) domain and were involved in regulating the expression of genes in B-lymphocytes, adipocytes, neuronal cells, and several other cell types [40] . EBFs played specific important roles in regulating cells differentiation in all three embryonic germ layers [41] . The human genomes have four genes of EBF family (EBF1-EBF4) and studies have shown that EBF3 gene is silenced in diverse tumor cell lines, such as breast, bone, lung, and colorectal cancers [42] .
Mraz et al. [43] found that miR-650 targeted EBF3 to influence the proliferative capacity of B cells in chronic lymphocytic leukemia. (D) Transwell migration assay was performed with miR-NC, miR-23b-3p, or miR-23b-3p and EBF3 co-transfection. Cells in five random fields of view were observed and the migrated cells were counted (×200 magnification). (E) Transwell invasion assay was performed in cells transfected with miR-NC, miR-23b-3p, or miR-23b-3p and EBF3 co-transfection. Cells in five random fields of view were observed and the invaded cells were counted (×100 magnification). Each experiment was performed in triplicate. **P < 0.01.
Zhao et al. [44] indicated that EBF3 regulated tumor suppression with a transcriptional program. EBF3 has been demonstrated to be a prognostic marker which exhibits a great correlation with the overall survival by array comparative genomic hybridization techniques in mycosis fungoides and Sezary syndrome [45] . Similar studies suggested that the abnormalities of EBF3 play an important role with prognosis in Mycosis fungoide [46] .
In pancreatic ductal adenocarcinoma, EBF3 repressed cell proliferation and led to cell cycle arrest, growth suppression, and apoptosis [47] . In gastric carcinoma, EBF3 served as a tumor suppressor Immunofluorescence staining analysis was used to detect the expressions of epithelial markers (E-cadherin and ß-catenin) and mesenchymal markers (N-cadherin and Vimentin) in ESCC cell lines transfected with NC or EBF3. DAPI was used to visualize the nuclei. Each experiment was performed in triplicate. GAPDH was used as an internal control. **P < 0.01.
and an independent prognostic marker [48] . In head and neck SCC, frequent hypermethylation of the promoters of tumor suppressive gene EBF3 could help guide epigenetic therapy. Furthermore, EBF3 and other genes interacted with the components of the TGF-β pathway to increase proliferation and differentiation [49] . In pediatric acute myeloid leukemia, EBF3 could also inhibit proliferation [50] . In metastatic melanoma, the hypermethylation in EBF3 promoter might result in a candidate for epigenetic driver of metastasis [51] .
Although miR-23b-3p and EBF3 contribute to the tumorigenesis of diverse types of human cancers, the underlying biological mechanism of their interaction in ESCC is still unknown. Here, we found that miR-23b-3p was up-regulated in ESCC cells. MTT, migration, and invasion assays revealed that miR-23b-3p could induce the proliferation, invasion, and metastasis. Furthermore, we demonstrated that EBF3 could inhibit the proliferation, invasion, and metastasis. We also proved that EBF3 inhibited these processes through the upstream regulation of miR-23b-3p. Ultimately, we explored the functions of miR-23b-3p and EBF3 in EMT progress in ESCC. However, these results need to be confirmed in vivo in our future work, and more attention should be paid on these aspects and obtain more evidence in the effects of miR-23b-3p and EBF3 on ESCC therapy.
